Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma.
Paes T, Buelvas Mebarak J, Magnotto JC, Stamatiades GA, Kuang Y, Paweletz C, Laws ER, Grosek N, Carroll RS, Jeselsohn R, Mohan DR, Lerario AM, Truong MT, Bi WL, Reardon DA, Meredith DM, Kaiser UB, Abreu AP. Paes T, et al. Among authors: jeselsohn r. J Clin Endocrinol Metab. 2024 Sep 6:dgae615. doi: 10.1210/clinem/dgae615. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 39238355
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
Hinohara K, Wu HJ, Sébastien Vigneau, McDonald TO, Igarashi KJ, Yamamoto KN, Madsen T, Fassl A, Egri SB, Papanastasiou M, Ding L, Peluffo G, Cohen O, Kales SC, Lal-Nag M, Rai G, Maloney DJ, Jadhav A, Simeonov A, Wagle N, Brown M, Meissner A, Sicinski P, Jaffe JD, Jeselsohn R, Gimelbrant AA, Michor F, Polyak K. Hinohara K, et al. Among authors: jeselsohn r. Cancer Cell. 2019 Feb 11;35(2):330-332. doi: 10.1016/j.ccell.2019.01.012. Cancer Cell. 2019. PMID: 30753830 Free PMC article. No abstract available.
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. De Angelis C, et al. Among authors: jeselsohn r. Clin Cancer Res. 2021 Sep 1;27(17):4939. doi: 10.1158/1078-0432.CCR-21-2431. Clin Cancer Res. 2021. PMID: 34470810 No abstract available.
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.
Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, Carroll JS, Bowden M, Rao P, Long HW, Li F, Dowsett M, Schiff R, Brown M. Jeselsohn R, et al. Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4482-E4491. doi: 10.1073/pnas.1620993114. Epub 2017 May 15. Proc Natl Acad Sci U S A. 2017. PMID: 28507152 Free PMC article.
Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer.
Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Jänne PA, Paweletz CP, Lin NU, Krop IE, Barry WT, Winer EP, Brown M, Jeselsohn R. Kuang Y, et al. Among authors: jeselsohn r. NPJ Breast Cancer. 2018 Aug 2;4:22. doi: 10.1038/s41523-018-0075-5. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30083595 Free PMC article.
ESR1 activating mutations: From structure to clinical application.
Grinshpun A, Chen V, Sandusky ZM, Fanning SW, Jeselsohn R. Grinshpun A, et al. Among authors: jeselsohn r. Biochim Biophys Acta Rev Cancer. 2023 Jan;1878(1):188830. doi: 10.1016/j.bbcan.2022.188830. Epub 2022 Nov 4. Biochim Biophys Acta Rev Cancer. 2023. PMID: 36336145 Free article. Review.
76 results